Abeona (ABEO) CEO sells 29,985 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 29,985 shares of common stock in an open-market transaction. The sale occurred on March 31, 2026 at a weighted average price of $4.3849 per share, with individual trades between $4.31 and $4.43.

After the transaction, Seshadri directly held 1,430,423 shares of Abeona common stock. The filing states that the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024, indicating it was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 29,985 shares ($131,481)

Net Sell 1 txn

Insider Seshadri Vishwas

Role Chief Executive Officer

Sold 29,985 shs ($131K)

Type	Security	Shares	Price	Value
Sale	Common Stock	29,985	$4.3849	$131K

Holdings After Transaction: Common Stock — 1,430,423 shares (Direct)

Footnotes (1)

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.31 to $4.43 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 29,985 shares Weighted average sale price: $4.3849 per share Post-transaction holdings: 1,430,423 shares +2 more

5 metrics

Shares sold 29,985 shares Open-market sale on March 31, 2026

Weighted average sale price $4.3849 per share Average price reported for the sale transactions

Post-transaction holdings 1,430,423 shares Common stock directly owned after the sale

Sale price range $4.31–$4.43 per share Range of prices across multiple sale executions

Plan adoption date September 17, 2024 Date CEO adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seshadri Vishwas

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		S(1)		29,985	D	$4.3849(2)	1,430,423	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.31 to $4.43 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Vishwas Seshadri	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for its CEO?

Abeona Therapeutics reported that CEO Vishwas Seshadri sold 29,985 shares of common stock. The transaction was an open-market sale executed on March 31, 2026, reflecting a planned disposition rather than a newly announced strategic move.

At what price did the Abeona (ABEO) CEO sell his shares?

The CEO’s shares were sold at a weighted average price of $4.3849 per share. Individual trades took place in multiple transactions, with prices ranging from $4.31 to $4.43, as disclosed in the Form 4 filing’s detailed footnote.

How many Abeona (ABEO) shares does the CEO hold after this Form 4 sale?

Following the reported sale, CEO Vishwas Seshadri directly owns 1,430,423 shares of Abeona common stock. This post-transaction figure shows that the 29,985 shares sold represent a relatively small portion of his total disclosed holdings.

Was the Abeona (ABEO) CEO’s stock sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 trading plan adopted on September 17, 2024. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary, market-timed insider actions.

What does the price range in the Abeona (ABEO) CEO’s sale mean for investors?

The Form 4 notes a weighted average price and a sale range of $4.31 to $4.43. This indicates multiple executions within that band, typical for open-market trades, and underscores that $4.3849 is an average rather than a single transaction price.